An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome

AIDS

Volumn 13, Issue 5, 1999, Pages 565-573

  Aboulker, J P ^e   Babiker, A G ^a,c   Darbyshire, J H ^a   Flandre, P ^e   Gazzard, B ^b   Loveday, C ^c   Nunn, A J ^d  

^a Med Res Cncl Clinical Trials Unit   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e Mortimer Market Centre ^*

Author keywords

Antiretroviral therapy; CD4 cell count; Clinical outcome; HIV 1 RNA; Surrogate markers; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 0032989354     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199904010-00005     Document Type: Article

References (20)

1. 1. Delta Co-ordinating Committee; Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348 : 283-291.
2. 2. Hammer SM, Katzenstein DA, Hughes MD, et al. for The AIDS Clinical Trials Group Study 175 Study Team: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, N Engl J Med 1996, 335 ; 1081-1090.
3. 3. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337 : 725-733.
4. 4. Fleming TR, DeMets DI : Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996, 125 ; 605-613.
5. 5. Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stats in Med 1989, 8 ; 431-440.
6. 6. Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stats in Med 1992, 11 : 167-178.
7. 7. Choi S, Lagakos SW, Schooley RT, Volberding PA: CD4 lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993, 118 ; 674-680.
8. 8. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343 ; 871-882.
9. 9. Brun-Vezinet F, Boucher CAB, Loveday C, et al.: HIV-1 viral load, phenotype and resistance in a subset of naive participants from the Delta trial. Lancet 1997, 350 ; 983-990.
10. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334 : 426-431.
11. 11. Montaner J, de Masi R, Hill A and the Caesar Coordinating Committee: Validation of HIV-1 RNA and CD4 count as surrogate markers in the Caesar Trial. 6th European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, 11-15 October, 1997 [abstract 207] p. 20.
12. 12. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 300 CD4 cells per cubic millimeter. N Engl J Med 1996, 335 : 1091-1098.
13. 13. Delta Co-ordinating Committee and Delta Virology Committee: HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS 1999, 13 ; 57-65.
14. 14. Cox DR: Regression models and life-tables. J R Stat Soc 1972, 34 : 187-203.
15. 15. Durrleman S, Simon R: Flexible regression models with cubic splines. Stats in Med 1989, 8 : 551-561.
16. 16. Lin DY, Fleming TR, De Gruttola V: Estimating the proportion of treatment effect explained by a surrogate marker [abstract]. Stats in Med 1997, 16 : 1515-1527.
17. 17. De Gruttola V, Wulfsohn MS, Fischl MA, Tsiatis AA: Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J AIDS 1993, 6 ; 359.
18. 18. Lin DY, Fischl MA, Schoenfeld DA: Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in HIV clinical trials. Stats in Med 1993, 12 ; 835-842.
19. 19. De Gruttola V, Fleming T, Lin DY, Coombs R: Perspective: validating surrogate markers - are we being naive? J Infect Dis 1997, 175 : 237-246.
20. 20. Daniels MJ, Hughes MD: Meta-analysis for the evaluation of potential surrogate markers. Stats in Med 1997, 16 : 1965-1982.